Technical Analysis for MRKR - Marker Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical MRKR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | -1.96% | |
| Oversold Stochastic | Weakness | -1.96% | |
| 20 DMA Resistance | Bearish | -3.35% | |
| Shooting Star Candlestick | Bearish | -3.35% | |
| 180 Bearish Setup | Bearish Swing Setup | -3.35% | |
| Stochastic Buy Signal | Bullish | -3.35% | |
| Wide Bands | Range Expansion | -3.35% | |
| Oversold Stochastic | Weakness | -3.35% | |
| Narrow Range Bar | Range Contraction | -1.96% | |
| NR7 | Range Contraction | -1.96% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 10 DMA Resistance | 8 minutes ago |
| Down 2 % | 8 minutes ago |
| Down 1% | 37 minutes ago |
| Up 1% | 37 minutes ago |
| Fell Below Previous Day's Low | 37 minutes ago |
Get a Trading Assistant
- Earnings date: 05/10/2021
Marker Therapeutics, Inc. Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immunology Immune System Immunotherapy Treatment Of Cancer Oncology Cancer Treatments Cancer Immunotherapy Virotherapy Ovarian Cancer Tumor Immunotherapies Cell Therapy Her2 Hematological Malignancies Her2/Neu Solid Tumor T Cell Tumor Cell Ovarian Cancers Breast And Ovarian Cancer Tpi
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.77 |
| 52 Week Low | 1.32 |
| Average Volume | 3,934,641 |
| 200-Day Moving Average | 1.90 |
| 50-Day Moving Average | 2.42 |
| 20-Day Moving Average | 2.25 |
| 10-Day Moving Average | 2.14 |
| Average True Range | 0.22 |
| ADX | 10.89 |
| +DI | 23.11 |
| -DI | 22.58 |
| Chandelier Exit (Long, 3 ATRs ) | 2.65 |
| Chandelier Exit (Short, 3 ATRs ) | 2.43 |
| Upper Bollinger Band | 2.69 |
| Lower Bollinger Band | 1.81 |
| Percent B (%b) | 0.32 |
| BandWidth | 38.96 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.05 |
| MACD Histogram | -0.0122 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.26 | ||||
| Resistance 3 (R3) | 2.27 | 2.22 | 2.23 | ||
| Resistance 2 (R2) | 2.22 | 2.18 | 2.22 | 2.22 | |
| Resistance 1 (R1) | 2.16 | 2.16 | 2.14 | 2.15 | 2.21 |
| Pivot Point | 2.11 | 2.11 | 2.10 | 2.11 | 2.11 |
| Support 1 (S1) | 2.05 | 2.07 | 2.02 | 2.03 | 1.97 |
| Support 2 (S2) | 2.00 | 2.05 | 2.00 | 1.96 | |
| Support 3 (S3) | 1.94 | 2.00 | 1.95 | ||
| Support 4 (S4) | 1.92 |
